Aromatase Inhibition and Breast Cancer - W. Miller, R. Santeen

Presents evidence that letrozole, anastrozole, and exemestane have proven efficacy as second-line therapy and indicate increased antitumor effects and less toxicity than older aromatase inhibitors and progestins!

This reference provides a state-of-the-art assessment of drugs that inhibit the synthesis of estrogens-particularly agents used to treat breast cancer-and demonstrates how the endocrinological effects of the new generation of inhibitors translate into clinical benefits.

Trích dẫn:https://bit.ly/3fwVvuY